consistency of pacritinib in patients with mf: pooled analysis from persist-1 & persist-2
Published 1 year ago • 39 plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
2:18
results of persist-1 & persist-2 studies of pacritinib vs best alternative therapy in myelofibrosis
-
0:54
study design for persist-2 and other upcoming trials of pacritinib
-
1:31
risk-adjusted safety analysis of pacritinib for patients with mf
-
4:12
pacritinib for patients with mf across the cytopenic spectrum
-
2:04
design and results of persist-1 trial of pacritinib for myelofibrosis
-
1:46
the efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia
-
3:46
results of the phase iii persist-1 trial of pacritinib for myelofibrosis
-
2:18
updates on persist-1 trial of pacritinib for myelofibrosis
-
8:47
ipmns - fukuoka guidelines
-
3:54
summit study: safety & efficacy of bezuclastinib in patients with nonadvanced systemic mastocytosis
-
2:44
trial in progress: anti-slamf7 elotuzumab in jak2-mutated myelofibrosis
-
4:48
an insight into the management of cytopenias in mf
-
2:57
preliminary data from the manifest study: pelabresib in combination with ruxolitinib in mf
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
2:05
investigating the efficacy of tp-3654 in patients with myelofibrosis: results from phase i study
-
2:15
a phase i study investigating ruxolitinib and abemaciclib for primary or secondary myelofibrosis
-
1:49
phase ii trial-in-progress of itacitinib in patients with myelofibrosis
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
3:56
results of the phase ii titan study of caplacizumab in patients with attp
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl
-
1:31
pembrolizumab plus avd in chl: long-term follow-up of a phase ii study
-
1:30
recent advancements in bpdcn: diagnostic criteria, pathophysiology, and treatment